The political economics of cancer drug discovery and pricing
Open Access
- 1 December 2020
- journal article
- review article
- Published by Elsevier in Drug Discovery Today
- Vol. 25 (12) , 2149-2160
Abstract
No abstract availableKeywords
Funding Information
- Merck
This publication has 32 references indexed in Scilit:
- Value and cancer medicines—A personal viewJournal of Cancer Policy, 2017
- QALYs as a measure of value in cancerJournal of Cancer Policy, 2017
- How Much Longer Will We Put Up With $100,000 Cancer Drugs?Cell, 2017
- Innovation in the pharmaceutical industry: New estimates of R&D costsJournal of Health Economics, 2016
- Financial Returns on R&D: Looking Back at History, Looking Forward to Adaptive LicensingReviews on Recent Clinical Trials, 2015
- Methods for the estimation of the National Institute for Health and Care Excellence cost-effectiveness thresholdHealth Technology Assessment, 2015
- The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML expertsBlood, 2013
- The role of funding and policies on innovation in cancer drug developmentecancermedicalscience, 2010
- OFT, VBP: QED?Health Economics, 2007
- The political economy of the pharmaceutical industry.1986